Condition
Myeloablative
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Recombinant Human Thrombopoietin Rhtpo
Research Leaders
9 sponsors active, led by Guangzhou General Hospital of Guangzhou Military Command
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
100%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 4 (1)
Trial Status
Unknown1
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Recombinant Human Thrombopoietin Rhtpo1
Active Sponsors
- Guangzhou General Hospital of Guangzhou Military Command1
- Third Affiliated Hospital, Sun Yat-Sen University1
- Guangzhou Overseas Chinese Hospital,Guangdong1
- Guangdong No.2 Provincial People's Hospital1
- Guangdong Provincial People's Hospital1
Top Investigators
Department of Hematology, Nanfang Hospital
Related Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation1
- Delayed Platelet Engraftment1